ClinicalTrials.gg
Not yet recruitingNCT07715266Updated Aug 13, 2026

POST CATARACT SURGERY DRY EYE DISEASE

An interventional study of NOX-01 in Dry Eye Disease (DED) and Cataract Surgery, sponsored by NOXELIS. Not yet recruiting at 2 sites in Spain. Open to participants aged 18 Years to 78 Years. Per ClinicalTrials.gov, last updated 2026-08-13.

Sponsored by NOXELIS · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years to 78 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Dry Eye Syndromes with a site in Spain — 3 open to participants now, 4 under way, none of them phase 3. Dry Eye Syndromes · Spain.

Planned enrollment
29th of 41
33 · median 60
Started
2026
the only one that year
No phase
21 of 44
1 open now
Registered
43rd of 44
by date

Among the 44 studies in Dry Eye Syndromes with a site in Spain, this one is the 29th largest by planned enrollment of the 41 interventional ones that give a count, is the only one that started in 2026, is one of 21 with no phase, and was the 43rd registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

3 of the 44 studies in Dry Eye Syndromes with a site in Spain are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 78 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Dry Eye Syndromes with a site in Spain, or all of them as a file.
02

Study summary

Cataract surgery is one of the most frequent and successful interventions currently undertaken in medicine. However, a significant number of patients who underwent cataract surgery still complain about postoperative symptoms, such as irritation, pain, dryness, burning sensation, and foreign body sensation. Dry eye disease (DED) is a common postoperative symptom, with a prevalence fluctuating from 9.8% to 34% depending on the studies. The onset, or the worsening, of DED signs and symptoms usually occurs in the first postoperative week and may last for months affecting the satisfaction and quality of life of the patient. The reasons of dry eye development after cataract surgery include thermal and light toxicity from the microscope, corneal epithelial damage, repeated drying and irrigation of ocular surface during operation, sterilization of conjunctival sac and eyelid with chemicals, transection of the corneal nerves by corneal incision, use of topical anaesthetics, and preservatives in topical eye drops. The mainstay of post-cataract surgery DED prevention and management is the treatment with non-preserved artificial tears, which has shown good results in terms of the reduction in postoperative DED signs and symptoms in previous clinical studies.

NOX-01 Ocular Drops is a medical device not already CE-marked. It is a preservative-free ophthalmic lubricant solution intended to be used in cases of moderate to severe dry eye in adults, regardless of gender. NOX-01 is a biomimetic emulsion which lubricates and protects the corneal surface, limiting the inflammation due to dry eye and stabilizing the tear film.

The primary objective of this pilot and pre-market study is to assess the tolerance of NOX-01 on eye dryness syndrome before and after a cataract surgery, in patients with pre-existing mild to moderate DED, during 84 days of use (12 weeks). The performance of the product, used 4 times per day, in improving signs of symptoms of DED, will also be assessed before and after cataract surgery, as well as subject and investigator satisfaction.

03

Conditions studied

  • Dry Eye Disease (DED)
  • Cataract Surgery

Browse trials for

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 2. Age: > 18 years and less than 78 years old. 3. Subject who requires a unilateral cataract surgery (phacoemulsification and intra ocular lens implantation) or bilateral cataract surgery with delay of maximum 4 days between two eyes operation.

    4. Subject with mild to moderate dry eye at the pre-operative visit with the following scores:

    • OSDI (Ocular Surface Disease Index) ≥ 13 and ≤ 32
    • Schirmer test in the operated eye ≥ 5 mm/5min and ≤ 15 mm/5min And/or
    • Non-invasive break-up time (NIBUT) in the operated eye: sum of 3 measurement ≥ 5 sec and ≤ 15 sec 5. Patient who did not use artificial tears 1 week before the screening visit. 6. Patient having given freely and expressly his . 7. Patient psychologically able to understand the study related information and to give a written informed consent.

      8. Female of should use a regimen recognized as effective since at least 12 weeks before screening visit, during all the study and at least 1 month after the study end.

Exclusion criteria

Exclusion Criteria:

In terms of population

  1. Pregnant or nursing woman or planning a pregnancy during the study.
  2. Subject who had been deprived of their freedom by administrative or legal decision or who is under guardianship.
  3. Subject in a social or sanitary establishment.
  4. Subject suspected to be non-compliant according to the investigator's judgment.
  5. Patient using contact lens during screening period and the entire study (even if prescribed by the investigator after surgery).

    In terms of associated pathology

  6. Subject with a condition or receiving a medication which, in the investigator's judgment, put the subject at undue risk.
  7. Subject with severe eye dryness
  8. Patient with palpebral malposition with a tendency to incomplete blinking +/- scleral show
  9. Patient with general pathologies that can cause dry eye syndrome like: thyroid disorder, cutaneous rosacea, acne and/or iatrogenic effects of isotretinoin treatment.
  10. Presence of ocular comorbidities such as glaucoma, uveitis or cystoid macular oedema.
  11. Neuropathic causes of dry eye ( long-standing contact lens wearing, previous ocular herpes infections)
  12. Past or active ocular surface diseases (any corneal disease, cicatricial conjunctivitis, ocular surface burns, keratinization of the eyelid margin, Sjogren syndrome, corneal trauma)
  13. Ocular or general factors predisposing the patient to an increased risk for intraoperative complications, according to investigator's evaluation
  14. Know to any component of the study product Relating to previous or ongoing treatment
  15. Subject with other ocular surgery in the 12 previous months.
  16. Subject with lid surgery in the 3 previous months
  17. Subject who received systemic non-steroidal anti-inflammatory drugs, , corticoids or any medication that could interfere with lacrimal function during the 3 weeks prior to the study.
  18. Subject who received topical antibiotics, topical NSAIDs, topical or topical cyclosporine in either eye in the past month.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    NOX-01 Treatment

    1 drop per eye, four times per day, in the operated eye

    Device: NOX-01

Interventions

  • DeviceNOX-01

    1 drop per eye, four times per day, in the operated eye

06

What researchers measure

Primary outcomes

  1. Severe ocular symptoms

    Tolerance of NOX-01 : Proportion of subject with at least one severe symptom.

    Time frame: Day 1, Day 7, Day 28 and Day 84

Secondary outcomes

  1. Conjunctival hyperaemia using the McMonnies photographic scale

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye. Scale from 0 to 5 (worse)

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28 and D84

  2. Non-invasive film Break-Up Time (NIBUT)

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye The specular image of a pattern projected onto the tear film, is examined with a corneal topographer. The time taken for the image to degrade, after the last blink, is the NIBUT, expressed in seconds. Each site will evaluate NIBUT according to their own device and procedure (Topcon CA-800 Catalog, Atlas 9000, Pentacam HD, Atlas 500 or Pentacam AXL Wave). The NIBUT will be assessed three times and the sum of these three measurements will be calculated.

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28 and Day 84

  3. Schirmer test result

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye The results are expressed in mm/5min

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28 and Day 84

  4. Cornea and conjunctiva staining (Oxford score)

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye Scale from 1 to 15 (worse)

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28 and Day 84

  5. OSDI score

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye Scale from 0 to 100 (worse)

    Time frame: 7 day before surgery, D1, Day 7, Day 28 and Day 84

  6. Epithelial Thickening Mapping : Total pachymetry (total thickness of the cornea)

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point, in the first operated eye Express in micrometer

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28

  7. Intra-Ocular Pressure (IOP)

    Change from baseline before cataract surgery (Day-7) and from baseline after cataract surgery (Day1) at each applicable time point for the following parameters, in the first operated eye

    Time frame: 7 day before surgery, Day 1, Day 84

  8. Symptoms evaluated by the patient using a VAS

    Visual Analog Scale Symptom Index : from 0% to 100% (worse)

    Time frame: Day 7, Day 28, Day 84

  9. Global tolerance score evaluated by the investigator

    On a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)

    Time frame: Day 84

  10. Global tolerance score evaluated by the patient

    On a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)

    Time frame: Day 84

  11. Global performance score evaluated by the investigator

    On a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)

    Time frame: Day 84

  12. Global performance score evaluated by the patient

    On a 4-point scale (Unsatisfactory, Not very satisfactory, Satisfactory, Very satisfactory)

    Time frame: Day 84

  13. Patient satisfaction

    Questionnaire

    Time frame: Day 28 and Day 84

  14. Adverse event

    Adverse event collection

    Time frame: 7 day before surgery, Day 1, Day 7, Day 28, Day 84

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for May 2027, 8 months later.

Of 115 industry-sponsored interventional studies with no phase under Dry Eye Syndromes, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 14. This study's planned 8 months is below that.

Counting every sponsor, half of 315 studies reached it within 10 months; a quarter within 4 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2026
First posted
Jul 20, 2026
StartEst.
Sep 2026
Primary completionEst.
May 2027
CompletionEst.
May 2027
Last update
Aug 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07715266
Lead sponsor
NOXELIS
Collaborators
Eurofins Dermscan Pharmascan
Responsible party
Sponsor
First posted
Jul 20, 2026
Start date
Sep 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
May 2027 (estimated)
Last update
Aug 13, 2026

Study contacts

Gautier LALEVEE
Contact
g.lalevee@noxelis.com
+33 7 85 89 31 39

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion